Overview

Phase I Biomarker Study (BMS-936558)

Status:
Completed
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Ono Pharma USA Inc
Treatments:
Antibodies, Monoclonal
Nivolumab